CO6260098A2 - Peptido antimicrobianos que exhiben un amplio rango de acividad antimicrobiana para bacterias gram positivas y gram negativas, asi como tambien hongos, moho y virus - Google Patents

Peptido antimicrobianos que exhiben un amplio rango de acividad antimicrobiana para bacterias gram positivas y gram negativas, asi como tambien hongos, moho y virus

Info

Publication number
CO6260098A2
CO6260098A2 CO10023449A CO10023449A CO6260098A2 CO 6260098 A2 CO6260098 A2 CO 6260098A2 CO 10023449 A CO10023449 A CO 10023449A CO 10023449 A CO10023449 A CO 10023449A CO 6260098 A2 CO6260098 A2 CO 6260098A2
Authority
CO
Colombia
Prior art keywords
antimicrobial
cationic peptide
tat
hiv
compositions
Prior art date
Application number
CO10023449A
Other languages
English (en)
Inventor
Hongran Fan Stone
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CO6260098A2 publication Critical patent/CO6260098A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención proporciona péptidos antimicrobianos que exhiben un amplio rango de actividad antimicrobiana para bacterias gram positivas y gran negativas, así como también hongos, moho, y virus. El péptido antimicrobiano de la invención es un péptido catiónico, y puede contener un HIV-TAT o la secuencia inversa HIV-TAT, o el derivado de los mismos. La presente invención proporciona adicionalmente composiciones antimicrobianas que contienen el péptido catiónico. Tales composiciones son especialmente útiles para aplicación tópica a la piel, cabello, uñas, vagina, uretra, oído, cavidad oral, pasaje nasal, sistema respiratorio, región oftálmica, y varias regiones de mucosa. Las composiciones de la presente invención mejoran la afección y/o apariencia de la región tratada, y son adecuadas para uso de rutina y/o a largo plazo, por ejemplo, evitan o evitan la recurrencia de infección microbiana. La presente invención proporciona adicionalmente equipos para uso en mejorar la afección o apariencia de la piel, uñas, o área tratada. Estos equipos pueden facilitar el uso, almacenamiento a largo plazo, y/o eficacia de las composiciones. 1.- Una composición que consiste esencialmente de un péptido catiónico en una cantidad efectiva para actividad antimicrobiana, y un portador y/o diluyente farmacéuticamente o cosméticamente aceptable, en donde dicho péptido catiónico comprende por lo menos 50% de residuos Arg y Lys. 2.- La composición de la reivindicación 1 en donde dicho péptido catiónico contiene un HIV-TAT, HIV-TAT inverso, o el derivado de los mismos. 3.- La composición de la reivindicación 1 o 2, en donde la composición se formula para administración tópica.
CO10023449A 2007-07-26 2010-02-26 Peptido antimicrobianos que exhiben un amplio rango de acividad antimicrobiana para bacterias gram positivas y gram negativas, asi como tambien hongos, moho y virus CO6260098A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95205907P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
CO6260098A2 true CO6260098A2 (es) 2011-03-22

Family

ID=40281862

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10023449A CO6260098A2 (es) 2007-07-26 2010-02-26 Peptido antimicrobianos que exhiben un amplio rango de acividad antimicrobiana para bacterias gram positivas y gram negativas, asi como tambien hongos, moho y virus

Country Status (25)

Country Link
US (1) US8623811B2 (es)
EP (3) EP3741380A1 (es)
JP (5) JP5401457B2 (es)
KR (4) KR101717275B1 (es)
CN (2) CN102872447B (es)
AU (1) AU2008278593B2 (es)
BR (3) BRPI0813627B1 (es)
CA (1) CA2694046C (es)
CO (1) CO6260098A2 (es)
CR (1) CR11239A (es)
CY (2) CY1118503T1 (es)
DK (2) DK2178549T3 (es)
ES (2) ES2609914T3 (es)
HK (1) HK1180237A1 (es)
HR (1) HRP20161722T1 (es)
HU (1) HUE031136T2 (es)
IL (3) IL203173A (es)
LT (1) LT2178549T (es)
MX (1) MX2010000916A (es)
NZ (1) NZ582459A (es)
PL (1) PL2178549T3 (es)
PT (2) PT2178549T (es)
SG (1) SG188128A1 (es)
SI (1) SI2178549T1 (es)
WO (1) WO2009015385A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093639A1 (en) * 2006-12-29 2010-04-15 Revance Therapeutics, Inc. Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
PT2178549T (pt) * 2007-07-26 2016-12-20 Revance Therapeutics Inc Péptido antimicrobiano e suas composições
US8933013B2 (en) 2007-12-05 2015-01-13 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
ES2524312T3 (es) 2008-03-14 2014-12-05 Allergan, Inc. Ensayos de actividad de serotipo A de toxina botulínica de base inmunológica
DK2379104T3 (en) 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
EP2413947B1 (en) 2009-04-01 2020-04-29 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
SG177357A1 (en) 2009-06-25 2012-02-28 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
FR2997304B1 (fr) 2012-10-26 2017-07-07 Isp Investments Inc Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
EP4115897A1 (en) * 2015-09-17 2023-01-11 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
US10105381B2 (en) * 2016-05-23 2018-10-23 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10144767B2 (en) * 2016-08-18 2018-12-04 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and coatings
CA3044219A1 (en) * 2016-11-21 2018-05-24 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. TRANSMUCOSAL BOTULINUM TOXIN COMPOSITIONS, KITS, AND METHODS FOR TREATMENT OF BLADDER DISORDER
CN107353334B (zh) * 2017-08-30 2020-02-07 四川大学 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用
CN107556374B (zh) * 2017-08-30 2020-02-07 四川大学 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用
JP7266202B2 (ja) * 2018-02-19 2023-04-28 株式会社ファンケル 化粧料及び抗炎症剤

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
WO1993021941A1 (en) * 1992-04-23 1993-11-11 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
AU685862B2 (en) * 1993-10-22 1998-01-29 Allelix Biopharmaceuticals Inc. Treatment of cytomegalovirus infection
EP1421948B1 (en) 1993-12-28 2008-10-08 Allergan, Inc. Use of botulinum toxins against sweating in humans
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DE69637731D1 (de) * 1995-08-23 2008-12-11 Univ British Columbia Antimikrobielle kationische peptide und methoden zu ihrer identifizierung
US6043218A (en) * 1996-10-22 2000-03-28 Medical University Of South Carolina Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
JP2002505077A (ja) * 1997-12-10 2002-02-19 ワシントン大学 抗病原体システムおよびその使用方法
WO1999031261A1 (en) * 1997-12-12 1999-06-24 Onyx Pharmaceuticals, Inc. SELECTIVE KILLING AND DIAGNOSIS OF p53+ NEOPLASTIC CELLS
BR9914891A (pt) 1998-10-27 2001-07-17 Mayo Foundation Processos para aperfeiçoamento de cura de ferimento
JP2002531113A (ja) 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
KR100638150B1 (ko) 1998-12-23 2006-10-26 이데아 악티엔게젤샤프트 생체내에서 국부적인 비침습성 용도로 사용되는 개선된 제제
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US20030236214A1 (en) * 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
ATE437647T1 (de) 2001-02-16 2009-08-15 Cellgate Inc Transporter mit beabstandeten arginin-teilchen
CA2446458A1 (en) * 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
EP1461084A2 (en) * 2001-12-11 2004-09-29 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
WO2003072049A2 (en) 2002-02-21 2003-09-04 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP4154218B2 (ja) * 2002-11-27 2008-09-24 寛紀 高麗 新規抗菌性ポリペプチドとその利用
IL153557A0 (en) * 2002-12-19 2003-07-06 Yitzchak Hillman Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
NZ540506A (en) * 2002-12-19 2008-09-26 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
AU2004209981B2 (en) * 2003-02-01 2009-02-26 Janssen Sciences Ireland Uc Active immunization to generate antibodies to soluble A-beta
WO2004084805A2 (en) * 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
MXPA06002828A (es) * 2003-09-12 2006-06-23 Univ British Columbia Efectores de determinacion de inmunidad innata.
JP2005120050A (ja) * 2003-10-20 2005-05-12 Toagosei Co Ltd 新規抗菌性ペプチドとその利用
PT2985039T (pt) 2004-03-03 2018-11-09 Revance Therapeutics Inc Aplicação tópica e administração transdérmica de toxinas botulínicas
EP1734984A4 (en) * 2004-03-03 2009-07-29 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL DIAGNOSIS AND THERAPEUTIC TRANSPORT
PT1778720E (pt) * 2004-08-18 2010-11-29 Novabiotics Ltd Péptidos antimicrobianos compreendendo um motivo com arginina e/ou lisina
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
WO2006050611A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
EP1661912A1 (en) 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
JP2006238751A (ja) * 2005-03-02 2006-09-14 Toagosei Co Ltd ベロ毒素結合性を有する抗菌ペプチド及びその利用
ATE507236T1 (de) 2005-03-03 2011-05-15 Revance Therapeutics Inc Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids
RU2007136616A (ru) 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрескожного введения ботулинового токсина
KR20080006568A (ko) 2005-03-30 2008-01-16 레반스 테라퓨틱스, 아이엔씨. 여드름 치료용 조성물 및 방법
EP1948230A4 (en) 2005-11-17 2010-03-10 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL ADMINISTRATION OF BOTULINUM TOXIN CONTAINING LESS NON-TOXIC PROTEINS
WO2008082889A2 (en) 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
US20100093639A1 (en) 2006-12-29 2010-04-15 Revance Therapeutics, Inc. Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
PT2178549T (pt) * 2007-07-26 2016-12-20 Revance Therapeutics Inc Péptido antimicrobiano e suas composições
DK2379104T3 (en) 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations

Also Published As

Publication number Publication date
BR122019000266B1 (pt) 2021-09-14
SI2178549T1 (sl) 2017-08-31
HK1180237A1 (zh) 2013-10-18
BRPI0813627B1 (pt) 2021-09-14
CY1123176T1 (el) 2021-10-29
CN101842107B (zh) 2014-04-23
CA2694046C (en) 2023-09-12
US8623811B2 (en) 2014-01-07
EP2178549A4 (en) 2014-02-19
SG188128A1 (en) 2013-03-28
EP3741380A1 (en) 2020-11-25
JP2020169190A (ja) 2020-10-15
BR122019000258B1 (pt) 2021-09-14
KR101717275B1 (ko) 2017-03-16
NZ582459A (en) 2012-05-25
KR20170016031A (ko) 2017-02-10
ES2805225T3 (es) 2021-02-11
HUE031136T2 (en) 2017-07-28
EP3120862A1 (en) 2017-01-25
IL223785A (en) 2015-02-26
JP2014076993A (ja) 2014-05-01
CN102872447A (zh) 2013-01-16
KR102088949B1 (ko) 2020-03-13
IL203173A (en) 2014-12-31
JP2017002057A (ja) 2017-01-05
WO2009015385A1 (en) 2009-01-29
EP2178549A1 (en) 2010-04-28
CN101842107A (zh) 2010-09-22
KR20180031824A (ko) 2018-03-28
JP5965884B2 (ja) 2016-08-10
EP2178549B1 (en) 2016-09-14
US20100215591A1 (en) 2010-08-26
KR20100047867A (ko) 2010-05-10
MX2010000916A (es) 2010-06-02
AU2008278593A1 (en) 2009-01-29
PT3120862T (pt) 2020-06-25
HRP20161722T1 (hr) 2017-02-10
CA2694046A1 (en) 2009-01-29
DK3120862T3 (da) 2020-06-22
CR11239A (es) 2010-06-29
JP5401457B2 (ja) 2014-01-29
PL2178549T3 (pl) 2017-03-31
DK2178549T3 (en) 2017-01-09
JP2019006791A (ja) 2019-01-17
PT2178549T (pt) 2016-12-20
AU2008278593B2 (en) 2015-04-09
EP3120862B1 (en) 2020-04-29
KR101722038B1 (ko) 2017-04-03
IL223784A (en) 2015-02-26
BRPI0813627A2 (pt) 2014-12-23
LT2178549T (lt) 2017-01-25
JP6722241B2 (ja) 2020-07-15
ES2609914T3 (es) 2017-04-25
CY1118503T1 (el) 2017-07-12
CN102872447B (zh) 2015-09-30
JP2010534684A (ja) 2010-11-11
AU2008278593A2 (en) 2011-05-12
KR20150090268A (ko) 2015-08-05

Similar Documents

Publication Publication Date Title
CO6260098A2 (es) Peptido antimicrobianos que exhiben un amplio rango de acividad antimicrobiana para bacterias gram positivas y gram negativas, asi como tambien hongos, moho y virus
US4006218A (en) Potentiated medicaments
US4091090A (en) Potentiated anesthetics
US20120316103A1 (en) Cyclic antimicrobial peptides
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
EP2496215B1 (en) Antimicrobial and anti-acne formulations
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
EA200500804A1 (ru) Топические противоинфекционные композиции
WO2003018619A3 (en) Antimicrobial and anti-inflammatory peptides
WO2006006195B1 (en) Antibacterial peptides and analogues thereof
EP4021476A1 (en) Synthetic antimicrobial peptides
WO2008035243A2 (en) Composition for treatment of burns and wounds
JP6124139B2 (ja) 低赤血球溶解性の抗微生物ペプチド、医薬組成物およびその使用
WO2006088945A3 (en) Granulysin peptides and methods of use thereof
ATE292117T1 (de) Zusammensetzungen zur behandlung von hautkrankheiten
AR053688A1 (es) Composicion farmaceurtica y su uso
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
ES2400734T3 (es) Péptidos ciclicos antimicrobianos
BR0110255A (pt) Cromenilmetil pirimidinadiaminas como agentes antibacterianos
ES2208367T3 (es) Composicion antiseptica.
CA2400872A1 (en) Cyclic hexapeptide derivatives
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
WO2012046922A1 (en) Novel use of antimicrobial peptides in regeneration of skin cells
CN112076252A (zh) 一种臭氧抑菌凝胶及其制备方法

Legal Events

Date Code Title Description
FC Application refused